Transforming Commercial Pharma with Agentic AI

The Next Frontier: Transforming Commercial Pharma with Agentic AI

Sign up for the whitepaper and learn how Agentic AI is set to disrupt pharma’s commercial engagement - and why acting now is key to staying ahead. Explore how a strategic approach to AI adoption can help pharma scale impact, optimize operations, and unlock lasting value.

Read more
filters
AI Transformation
Customer Engagement & Experience
Personalization at Scale
Moving Towards End-To-End Process Transformation

The pharmaceutical industry stands at a critical crossroads. Traditional commercial engagement models are losing effectiveness in a world demanding greater personalization, digital convenience, and precision. Enter the next big disruptor: Agentic AI.

This whitepaper explores how pharma companies can transition from siloed AI applications to fully autonomous, AI-driven processes - transforming how they engage with healthcare professionals (HCPs) and patients alike.

Moving Towards End-To-End Process Transformation

The pharmaceutical industry stands at a critical crossroads. Traditional commercial engagement models are losing effectiveness in a world demanding greater personalization, digital convenience, and precision. Enter the next big disruptor: Agentic AI.

This whitepaper explores how pharma companies can transition from siloed AI applications to fully autonomous, AI-driven processes - transforming how they engage with healthcare professionals (HCPs) and patients alike.

Moving Towards End-To-End Process Transformation

The pharmaceutical industry stands at a critical crossroads. Traditional commercial engagement models are losing effectiveness in a world demanding greater personalization, digital convenience, and precision. Enter the next big disruptor: Agentic AI.

This whitepaper explores how pharma companies can transition from siloed AI applications to fully autonomous, AI-driven processes - transforming how they engage with healthcare professionals (HCPs) and patients alike.

Moving Towards End-To-End Process Transformation

The pharmaceutical industry stands at a critical crossroads. Traditional commercial engagement models are losing effectiveness in a world demanding greater personalization, digital convenience, and precision. Enter the next big disruptor: Agentic AI.

This whitepaper explores how pharma companies can transition from siloed AI applications to fully autonomous, AI-driven processes - transforming how they engage with healthcare professionals (HCPs) and patients alike.

Moving Towards End-To-End Process Transformation

The pharmaceutical industry stands at a critical crossroads. Traditional commercial engagement models are losing effectiveness in a world demanding greater personalization, digital convenience, and precision. Enter the next big disruptor: Agentic AI.

This whitepaper explores how pharma companies can transition from siloed AI applications to fully autonomous, AI-driven processes - transforming how they engage with healthcare professionals (HCPs) and patients alike.

Moving Towards End-To-End Process Transformation

Key Challenges Addressed
  • Shrinking access to HCPs and diminishing impact of traditional sales models
  • Need for seamless omnichannel experiences tailored to individual preferences
  • Struggles in identifying high-potential patients early and effectively

Key Challenges Addressed
  • Shrinking access to HCPs and diminishing impact of traditional sales models
  • Need for seamless omnichannel experiences tailored to individual preferences
  • Struggles in identifying high-potential patients early and effectively

Key Challenges Addressed
  • Shrinking access to HCPs and diminishing impact of traditional sales models
  • Need for seamless omnichannel experiences tailored to individual preferences
  • Struggles in identifying high-potential patients early and effectively

Key Challenges Addressed

  • Shrinking access to HCPs and diminishing impact of traditional sales models
  • Need for seamless omnichannel experiences tailored to individual preferences
  • Struggles in identifying high-potential patients early and effectively

Key Challenges Addressed

  • Shrinking access to HCPs and diminishing impact of traditional sales models
  • Need for seamless omnichannel experiences tailored to individual preferences
  • Struggles in identifying high-potential patients early and effectively

Key Challenges Addressed

What You’ll Discover in the Whitepaper
  1. A walkthrough of the AI evolution - from traditional automation to the rise of Agentic AI
  2. A scenario showcasing how AI agents orchestrate end-to-end engagement for a new narcolepsy therapy
  3. A strategic blueprint for how pharma leaders can start scaling AI through connected use cases today - paving the way for autonomous, Agentic AI-driven engagement models tomorrow.

What You’ll Discover in the Whitepaper
  1. A walkthrough of the AI evolution - from traditional automation to the rise of Agentic AI
  2. A scenario showcasing how AI agents orchestrate end-to-end engagement for a new narcolepsy therapy
  3. A strategic blueprint for how pharma leaders can start scaling AI through connected use cases today - paving the way for autonomous, Agentic AI-driven engagement models tomorrow.

What You’ll Discover in the Whitepaper
  1. A walkthrough of the AI evolution - from traditional automation to the rise of Agentic AI
  2. A scenario showcasing how AI agents orchestrate end-to-end engagement for a new narcolepsy therapy
  3. A strategic blueprint for how pharma leaders can start scaling AI through connected use cases today - paving the way for autonomous, Agentic AI-driven engagement models tomorrow.

What You’ll Discover in the Whitepaper

  1. A walkthrough of the AI evolution - from traditional automation to the rise of Agentic AI
  2. A scenario showcasing how AI agents orchestrate end-to-end engagement for a new narcolepsy therapy
  3. A strategic blueprint for how pharma leaders can start scaling AI through connected use cases today - paving the way for autonomous, Agentic AI-driven engagement models tomorrow.

What You’ll Discover in the Whitepaper

  1. A walkthrough of the AI evolution - from traditional automation to the rise of Agentic AI
  2. A scenario showcasing how AI agents orchestrate end-to-end engagement for a new narcolepsy therapy
  3. A strategic blueprint for how pharma leaders can start scaling AI through connected use cases today - paving the way for autonomous, Agentic AI-driven engagement models tomorrow.

What You’ll Discover in the Whitepaper

Why It Matters

Agentic AI doesn’t just support your teams - it takes the lead. From HCP targeting to AI-powered clinical assistants and ongoing treatment monitoring, this tool unlocks:

  • Higher customer engagement
  • More timely and tailored decision-making
  • Sustainable competitive advantage

Why It Matters

Agentic AI doesn’t just support your teams - it takes the lead. From HCP targeting to AI-powered clinical assistants and ongoing treatment monitoring, this tool unlocks:

  • Higher customer engagement
  • More timely and tailored decision-making
  • Sustainable competitive advantage

Why It Matters

Agentic AI doesn’t just support your teams - it takes the lead. From HCP targeting to AI-powered clinical assistants and ongoing treatment monitoring, this tool unlocks:

  • Higher customer engagement
  • More timely and tailored decision-making
  • Sustainable competitive advantage

Why It Matters

Agentic AI doesn’t just support your teams - it takes the lead. From HCP targeting to AI-powered clinical assistants and ongoing treatment monitoring, this tool unlocks:

  • Higher customer engagement
  • More timely and tailored decision-making
  • Sustainable competitive advantage

Why It Matters

Agentic AI doesn’t just support your teams - it takes the lead. From HCP targeting to AI-powered clinical assistants and ongoing treatment monitoring, this tool unlocks:

  • Higher customer engagement
  • More timely and tailored decision-making
  • Sustainable competitive advantage

Why It Matters

Whitepaper

AI in pharma is moving beyond support tools to autonomous agents that transform engagement end-to-end. In this whitepaper, we explore the next frontier of Agentic AI - what it means for customer engagement, how to scale it responsibly, and the steps pharma companies must take today to stay ahead. Sign up to receive the full whitepaper and get practical guidance on turning AI potential into measurable business impact.

Interested in exploring how agnetic AI apply in your context?

Feel free to reach out for a deeper discussion.

Managing Director, Intellishore CH
Mikkel Møller Andersen

Managing Director, Intellishore CH
Mikkel Møller Andersen
Mikkel Møller Andersen
This is the default text value
Head of AI
Peter Nistrup

Head of AI
Peter Nistrup
Peter Nistrup
This is the default text value
Senior Manager, Intellishore CH
Rebecca Bub

Senior Manager, Intellishore CH
Rebecca Bub
Rebecca Bub
This is the default text value
filters
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
From Market Signal to Portfolio Decision

In this article, we map out the system behind a live opportunity assessment engine, and how it learns which signals matter to a decision and which are just noise.

Click to read more
Early Pipeline Opportunity Assessment
The application behind a live market opportunity assessment engine
The application behind a live market opportunity assessment engine
Market & Competitive Intelligence
Why Data & AI Portfolios Stall in Regulated Environments

A portfolio governance model for regulated environments: intake funnel, decision rights, benefit ownership, and the move into business-as-usual

Click to read more
Portfolio Governance
Four failure patterns, and how to design them out
Four failure patterns, and how to design them out
AI Transformation
Portfolio Governance
Assessing Market Opportunity at the Speed the Market Actually Moves

In the full article, we break down the two-level framework for assessing market opportunity, and how agentic AI fits into the process.

Click to read more
Early Pipeline Opportunity Assessment
How agentic AI turns market signals into a portfolio bet you can defend
How agentic AI turns market signals into a portfolio bet you can defend
Market & Competitive Intelligence
Rethinking Data Governance as a Business-Led Discipline

In this article, we outline why effective data governance starts with ownership, not tools - and how organizations can build the structures that make data trustworthy and scalable.

Click to read more
Data Governance
Rethinking Data Governance as a Business-Led Discipline
Rethinking Data Governance as a Business-Led Discipline
AI Transformation